Related Experiment Video
Updated: Jun 6, 2026
10:22
Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
New emerging drug-resistant malaria.
1Wiwanitkit House, Bangkhae, Bangkok Thailand.
International Journal of General Medicine
|December 1, 2010
Summary
Artemisinin-resistant malaria treatment remains challenging. Current artemisinin-based combination therapies are still the best option, but new antimalarial drugs are urgently needed.
Area of Science:
- Infectious Diseases
- Tropical Medicine
- Pharmacology
Background:
- Antimalarial drug resistance is a growing global health concern.
- Artemisinin resistance in Plasmodium falciparum malaria necessitates updated treatment strategies.
- Current treatment guidelines rely on artemisinin-based combination therapies (ACTs).
Purpose of the Study:
- To evaluate the optimal treatment for artemisinin-resistant malaria.
- To identify current therapeutic efficacies against resistant malaria strains.
- To highlight the need for novel antimalarial drug development.
Main Methods:
- Review of current clinical guidelines and treatment protocols for malaria.
- Analysis of efficacy data for artemisinin-based combination therapies (ACTs) in resistant malaria cases.
- Identification of research gaps and future drug development needs.
Main Results:
- Artemisinin-based combination therapies (ACTs) remain the most effective treatment for artemisinin-resistant malaria.
- No superior alternative treatment has surpassed the efficacy of current ACTs.
- A critical need exists for the development of new antimalarial drugs to combat resistance.
Conclusions:
- Current artemisinin-based combination therapies (ACTs) are the best available treatment for artemisinin-resistant malaria.
- The emergence of resistance underscores the importance of continuous surveillance and the development of novel antimalarial agents.
- Further research into new drug classes is essential to overcome emerging resistance patterns.
Related Concept Videos
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...